Wedbush Has Pessimistic Outlook of RARE Q3 Earnings

Key Points

• Wedbush analysts have downgraded Ultragenyx Pharmaceutical's Q3 2025 earnings per share estimate from ($1.00) to ($1.36), while maintaining a "Neutral" rating and a price target of $34.00.
• Ultragenyx reported earnings of ($1.17) per share for the most recent quarter, surpassing expectations, and achieved a revenue of $166.50 million, which is a 13.2% increase year-over-year.
• Despite a negative return on equity of 237.48% and various analysts lowering their price targets, the company's stock currently holds a consensus rating of "Moderate Buy" with an average target price of $81.50.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Research analysts at Wedbush reduced their Q3 2025 earnings per share estimates for Ultragenyx Pharmaceutical in a report released on Wednesday, August 6th. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will earn ($1.36) per share for the quarter, down from their previous forecast of ($1.00). Wedbush has a "Neutral" rating and a $34.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share. Wedbush also issued estimates for Ultragenyx Pharmaceutical's Q4 2025 earnings at ($1.42) EPS, FY2025 earnings at ($5.52) EPS, Q1 2026 earnings at ($1.22) EPS, Q2 2026 earnings at ($1.14) EPS, Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($1.01) EPS, FY2026 earnings at ($4.44) EPS and FY2027 earnings at ($3.08) EPS.

A number of other brokerages have also recently weighed in on RARE. Morgan Stanley dropped their price target on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, July 14th. Canaccord Genuity Group dropped their price target on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Cantor Fitzgerald dropped their price target on Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 6th. Wells Fargo & Company dropped their price target on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a research report on Thursday, July 10th. Finally, Guggenheim restated a "buy" rating and issued a $64.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $81.50.

Ultragenyx Pharmaceutical Stock Performance

Shares of Ultragenyx Pharmaceutical stock traded down $0.16 on Monday, reaching $28.82. 477,766 shares of the company were exchanged, compared to its average volume of 1,292,232. The company's 50-day moving average is $32.83 and its two-hundred day moving average is $36.45. The firm has a market cap of $2.78 billion, a price-to-earnings ratio of -5.21 and a beta of 0.25. Ultragenyx Pharmaceutical has a 1-year low of $25.81 and a 1-year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, topping analysts' consensus estimates of ($1.27) by $0.10. The business had revenue of $166.50 million for the quarter, compared to analysts' expectations of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%. The business's quarterly revenue was up 13.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.52) EPS.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the stock in a transaction on Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the completion of the transaction, the director directly owned 15,344 shares of the company's stock, valued at approximately $573,712.16. This trade represents a 13.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 5.50% of the company's stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RARE. Norges Bank bought a new position in Ultragenyx Pharmaceutical during the 2nd quarter valued at $35,765,000. Adage Capital Partners GP L.L.C. boosted its stake in shares of Ultragenyx Pharmaceutical by 81.6% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company's stock worth $77,815,000 after acquiring an additional 965,919 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Ultragenyx Pharmaceutical by 439.0% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,163,755 shares of the biopharmaceutical company's stock worth $42,314,000 after acquiring an additional 947,865 shares in the last quarter. Vestal Point Capital LP boosted its stake in shares of Ultragenyx Pharmaceutical by 100.0% during the 4th quarter. Vestal Point Capital LP now owns 1,500,000 shares of the biopharmaceutical company's stock worth $63,105,000 after acquiring an additional 750,000 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Ultragenyx Pharmaceutical by 28.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,218,942 shares of the biopharmaceutical company's stock worth $116,559,000 after acquiring an additional 706,519 shares in the last quarter. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.